...
首页> 外文期刊>Journal of cellular and molecular medicine. >MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1
【24h】

MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1

机译:MiR-200b在乳腺癌中的表达:预后标志物,并通过靶向Sp1作用于细胞增殖和凋亡

获取原文
获取原文并翻译 | 示例

摘要

MicroRNAs (miRNAs) have been identified as important post-transcriptional regulators involved in various biological and pathological processes of cells. In the present study, we investigated the roles and mechanisms of miR-200b in human breast cancer (BC). MiR-200b expression was carried out by qRT-PCR in human BC cell lines and clinical samples and the prognostic potential of miR-200b expression was further evaluated. In vitro, effects of miR-200b on BC cell proliferation, apoptosis and cell cycle distribution were tested by CCK-8 kit, flow cytometric analysis respectively. Luciferase assay and Western blot analysis were performed to validate the potential targets of miR-200b after the preliminary screening by employing open access software. We found that miR-200b was significantly down-regulated in both BC tissues and cell lines. The low expression of miR-200b was correlated with late TNM stage, negative oestrogen receptor and positive HER-2 status. Multivariate analysis showed that miR-200b expression was an independent prognostic predictor for BC patients. Integrated analysis identified Sp1 as a direct and functional target of miR-200b. Knockdown of Sp1 inhibited cell proliferation, induce apoptosis and act on cell cycle resembling that of miR-200b high expression. Our data demonstrates that miR-200b has potential to serve as prognostic biomarker and tumour suppressor for BC patients. As a direct and functional target of miR-200b, Sp1 and miR-200b both could be an exciting target for BC treatment strategy.
机译:MicroRNA(miRNA)已被确定为重要的转录后调控因子,参与细胞的各种生物学和病理过程。在本研究中,我们调查了miR-200b在人类乳腺癌(BC)中的作用和机制。通过qRT-PCR在人BC细胞系和临床样品中进行miR-200b表达,并进一步评估miR-200b表达的预后潜力。在体外,分别通过CCK-8试剂盒和流式细胞仪分析了miR-200b对BC细胞增殖,凋亡和细胞周期分布的影响。初步筛选后,通过使用开放获取软件,进行了荧光素酶测定和Western blot分析,以验证miR-200b的潜在靶标。我们发现,在BC组织和细胞系中miR-200b均显着下调。 miR-200b的低表达与TNM晚期,雌激素受体阴性和HER-2阳性有关。多变量分析表明,miR-200b表达是BC患者的独立预后指标。综合分析确定Sp1为miR-200b的直接和功能靶标。 Sp1的抑制可抑制细胞增殖,诱导细胞凋亡并作用于类似于miR-200b高表达的细胞周期。我们的数据表明,miR-200b有潜力作为BC患者的预后生物标志物和肿瘤抑制物。作为miR-200b的直接功能靶标,Sp1和miR-200b均可成为BC治疗策略中令人兴奋的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号